胸壁穿支皮瓣安全且可降低乳腺癌乳房切除术率:多中心队列研究
该国际多中心前瞻性队列研究纳入瑞典、英国和澳大利亚三家高容量中心的603例乳腺癌患者,评估胸壁穿支皮瓣用于保乳手术的实践模式和结局。中位随访22个月,总体并发症率8.6%,再次切除率15.9%,仅1.5%转为乳房切除术,无皮瓣丢失,局部复发率1.9%。结论认为胸壁穿支皮瓣是避免乳房切除术的有效选择,在经验丰富的中心安全可行。
要点
- 67.7%的患者中,术者提供胸壁穿支皮瓣以替代乳房切除术。
- 总体并发症率8.6%,多数为Clavien-Dindo I级(5.3%)。
- 中位随访22个月,局部复发率1.9%,无皮瓣丢失。
核心结论
- 胸壁穿支皮瓣是让更多女性避免乳房切除术的有效选择,在经验丰富的术者手中安全,应提供给合适患者。
研究设计与样本
- 国际多中心前瞻性队列研究,纳入瑞典Uppsala大学医院、英国Royal Marsden医院和澳大利亚Westmead乳腺癌研究所的603例乳腺癌患者(包括浸润前和浸润性),前瞻性记录提供胸壁穿支皮瓣的理由和手术结局。
主要发现
- 中位年龄54岁(IQR 48-63),中位BMI 25.0 kg/m2(IQR 22.5-28.1),中位肿瘤范围30 mm(IQR 19-45),中位乳房体积280 ml(IQR 216-430),中位计算切除比16%(IQR 9%-28%)。
- 67.7%的患者中,术者提供胸壁穿支皮瓣以避免乳房切除术;69.5%的患者作为日间手术完成。
- 总体并发症率8.6%,多数为Clavien-Dindo I级(5.3%的患者);再次切除率15.9%,仅1.5%转为乳房切除术;无皮瓣丢失。
- 中位随访22个月(范围12-98个月),局部复发率1.9%,远处复发率4.9%,乳腺癌相关死亡率1.7%。
临床怎么用
- 在经验丰富的中心,胸壁穿支皮瓣可作为保乳手术的肿瘤整形技术,用于避免乳房切除术。
- 术前应评估患者是否适合胸壁穿支皮瓣,包括肿瘤范围、乳房体积和计算切除比等。
局限性
- 研究未标准化患者选择、技术和结局,尚未达成共识。
- 仅纳入高容量中心,结果可能无法推广至经验较少的中心。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chest wall perforator flaps are emerging in oncoplastic breast conservation, mostly as an alternative to mastectomy. However, standardization and consensus on patient selection, techniques, and outcomes have not yet been reached. The aim of this international multicentre collaborative study was to explore practice patterns and outcomes in high-volume centres from different countries. METHODS: Patients with both pre-invasive and invasive breast cancer treated at the Uppsala University Hospital in Uppsala, Sweden, the Royal Marsden Hospital in London, UK, and the Westmead Breast Cancer Institute in Sydney, Australia, were included in this study. The rationale for offering chest wall perforator flaps and surgical outcomes were prospectively documented. RESULTS: In total, 603 patients were analysed median age of 54 (interquartile range (i.q.r.) 48-63) years, median BMI of 25.0 (i.q.r. 22.5-28.1) kg/m2, median tumour extent of 30 (IQR 19-45) mm, median breast volume of 280 (i.q.r. 216-430) ml, and median calculated resection ratio of 16% (i.q.r. 9%-28%). In 67.7%, the treating surgeon had offered chest wall perforator flaps to avoid mastectomy. The procedure was performed as day surgery in 69.5% of patients, with an overall complication rate of 8.6% and the majority of complications being classified as Clavien-Dindo grade I (5.3% of patients). The re-excision rate was 15.9%, with only 1.5% of patients converting to a mastectomy. There were no flap losses. At a median follow-up of 22 (range 12 to 98) months, rates of local recurrence, distant recurrence, and breast cancer-related mortality were 1.9%, 4.9%, and 1.7% respectively. CONCLUSION: Chest wall perforator flaps are a useful option to allow more women to avoid mastectomy. In experienced hands, the procedure is safe and should be offered to suitable patients.
引用
- Karakatsanis A, Meybodi F, Pantiora E, et al. Chest wall perforator flaps are safe and can decrease mastectomy rates in breast cancer surgery: multicentre cohort study. Br J Surg. 2024. PMID: 39485904. doi:10.1093/bjs/znae266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。